Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2023
Imdusiran data will be highlighted in late breaking presentation
WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop
novel therapeutics that target specific viral diseases, today announced that clinical data from the Company’s lead HBV focused asset, imdusiran (AB-729), an RNAi therapeutic, and preclinical data
from its oral PD-L1 inhibitor program, will be highlighted in oral and poster presentations, including a late breaking poster presentation at The American Association for the Study of Liver
Diseases (AASLD) – The Liver Meeting 2023, taking place from November 10-14, 2023 in Boston, MA.
Late-Breaking Abstract Acceptance:
Title: Preliminary Pharmacodynamics and Safety of Repeat Dosing of Imdusiran (AB-729) Followed by VTP-300 or Placebo in Virally-Suppressed, Non-Cirrhotic Subjects with Chronic
Hepatitis B (CHB)
Authors: Man-Fung Yuen, Kosh Agarwal, Stuart K. Roberts, Gin-Ho Lo, Chao-Wei Hsu, Wan-Long Chuang, Chi-Yi Chen, Pei-yuan Su, Sam Galhenage, Sheng-Shun Yang, Deana
Antoniello, Emily Thi, Susanne O’Brien, Louise Bussey, Elina Medvedeva, Timothy Eley, Deepa Patel, Tilly Varughese, Christine Espiritu, Sharie Ganchua, Christina Iott, Mark Anderson, Tiffany
Fortney, Gavin Cloherty, Tom Evans, Karen Sims
Lesen Sie auch
Regular Abstract Acceptances:
Abstract Number: 45559
Title: Baseline Nucleotide Polymorphisms Within HBV Target Site in Chronic Hepatitis B Subjects Do Not Impact HBsAg Reductions Mediated by RNA Interference Therapeutic
AB-729
Presentation Type: Poster #1459-C
Presentation Time: Friday, November 10: 12:00 – 1:00 PM ET – Poster Hall C
Authors: Christine Espiritu, Holly Micolochick Steuer, Andrzej Ardzinski, Varun Sharma, Timothy Eley, Karen D. Sims, Amy C.H. Lee, Rene Rijnbrand, Andrea Cuconati, Nagraj Mani,
Angela M. Lam, Michael J. Sofia, and Emily P. Thi
Data Summary: Single nucleotide polymorphisms (SNPs) in the imdusiran (AB-729) HBV target site were
identified in sequences obtained from a publicly available database and were observed at baseline in some chronic HBV subjects in AB-729-001. In vitro testing in an HBV cell-based model confirm
retention of AB-729 activity against tested variants suggesting that these SNPs have no apparent influence on individual or mean HBsAg declines observed in subjects treated with AB-729.